Showing results (211-220 of 295) with videos related to

Sort By:
Pageof 30
The European Respiratory Journal|April 20, 2023
Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension studyAaron Waxman, Ricardo Restrepo-Jaramillo, Thenappan Thenappan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 1, 2021
Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized TrialJeffrey R Strich, Xin Tian, Mohamed Samour, et al.
Genomics|May 11, 2010
Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosisMargaret C Emblom-Callahan, Mantej K Chhina, Oksana A Shlobin, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 31, 2026
Donor-derived cell-free DNA associated with increased risk of chronic lung allograft dysfunction and mortality: Are absolute levels better than percentage?Kellie Phipps, Hyesik Kong, Han Su, et al.
American Journal of Respiratory and Critical Care Medicine|February 14, 2024
Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE TrialLuca Richeldi, Courtney Schiffman, Jürgen Behr, et al.
The New England Journal of Medicine|January 13, 2021
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung DiseaseAaron Waxman, Ricardo Restrepo-Jaramillo, Thenappan Thenappan, et al.
The European Respiratory Journal|July 22, 2021
Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosisAmisha V Barochia, Maryann Kaler, Nargues Weir, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 22, 2022
Elevated cell-free DNA in respiratory viral infection and associated lung allograft dysfunctionKatrina Bazemore, Nitipong Permpalung, Joby Mathew, et al.
The Lancet. Respiratory Medicine|August 22, 2020
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trialJürgen Behr, Steven D Nathan, Wim A Wuyts, et al.
Annals of the American Thoracic Society|April 12, 2021
Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of Idiopathic Pulmonary FibrosisJean Pastre, Scott D Barnett, Inga Ksovreli, et al.
Pageof 30